Amgen "outperform," target price reduced

02.11.09 - Credit Suisse

NEW YORK, November 2 (newratings.com) - Analysts at Credit Suisse reiterate their "outperform" rating on Amgen (AMGN). The target price has been reduced from $75 to $70.